First clinical use of a heparin removal device: An alternative to protamine  by Conti, Vincent R. et al.
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 5 
Brief communications 10 15 
REQUESTED COMMENT CONCERNING: LIDOFLAZINE 
Willem Flameng, MD, Leuven, Belgium 
Lidoflazine is a drug that was developed by the Janssen 
Research Laboratories (Janssen Pharmaceutics, Beerse, 
Belgium) several decades ago but never became available 
on the international market. It has strong nucleoside 
transport inhibitory properties and can be classified as an 
ARA or adenosine regulating agent. 1Recently, there has 
been increasing interest in this type of drugs for myocar- 
dial protection, because they all enhance the tissue con- 
tent of adenosine in the myocardium. Adenosine is widely 
known for its cardioprotective properties against ischemic 
damage. 2 Accumulation of adenosine in the myocardium 
can be obtained by prevention of its breakdown (for 
example, by inhibition of its transport from the myocyte to 
the endothelial cell where adenosine is catabolized) or by 
stimulating its production. The latter can be done by 
infusing the precursor AICA riboside (5-amino-4-imida- 
zole carboxamide riboside). This drug is now under clin- 
ical investigation in large multicenter studies in the 
United States, Canada, and Europe. 
The study of Akpinar, Vanerman, and Wellens is 
interesting in so far as it demonstrates that extensive 
coronary bypass grafting can safely be done on the 
fibrillating heart using one single period of aortic cross- 
clamping combined with lidoßazine pretreatment. The 
clinical outcome was the same as when cardioplegia was 
used. However, the study does not provide scientific proof 
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for the cardioprotective properties of lidoflazine because 
the study was not placebo controlled. I realize, however, 
that a placebo-controlled study is unethical because pro- 
longed uninterrupted periods of ischemia, mainly on the 
fibrillating heart, will cause considerable myocardial dam- 
age. 3 The lack of significant release of creatine ldnase-MB 
as reported by Akpinar's group and the excellent clinical 
outcome suggest that myocardial injury is virtually absent 
in this setting. Although there is experimental evidence 
that lidoflazine will prevent myocardial damage ven after 
1 hour of normothermic global myocardial ischemia, 4 
these data cannot be extrapolated as such to the clinical 
situation and the diseased human heart. Therefore, I
believe that the technique described by Akpinar's group 
should not be advocated as generally applicable. Fast and 
skillful surgeons can use this technique, but they should 
realize that they might be balancing on a slack rope. 
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FIRST CLINICAL USE OF A HEPARIN REMOVAL DEVICE: AN ALTERNATIVE TO PROTAMINE 
Vincent R. Conti, MD, Roger A. Vertrees, BA, CCP, Joseph B. Zwischenberger, MD, and Mark Kurusz, CCP, 
Galveston, Tex. 
The reversal of heparin with protamine sulfate after 
termination of cardiopulmonary b pass (CPB) can elicit 
severe life-threatening reactions. These reactions can 
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occur despite such precautions as using a test dose of 
protamine, slow injection into the arterial side of the 
circulation, and premedication with steroids or H-l/H-2 
blockers. The adverse reactions occur more frequently in 
patients previously exposed to protamine, such as patients 
having second cardiac operations, patients with diabetes 
who receive neutral protamine Hagedorn (NPH) insulin, 
and patients with preoperative pulmonary hyperten- 
sion. As an alternative to protamine administration, the 
Heparin Removal Device was developed by Research 
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Fig. 1. Time course for ACT during the Heparin Re- 
moval Device (HRD) processing period. 
Medical, Inc., Midvale, Utah. The device is a commonly 
used extracorporeal p asmapheresis filter containing a
special resin that binds and immobilizes heparin rom 
circulating heparinized blood. In a pig model of CPB 
this device returned the activated clotting time (ACT) 
to baseline values from fully heparinized levels in 
approximately 20 minutes without any apparent adverse 
effects on other measured coagulation variables. 1 We 
report the frst clinical use of this device for life- 
threatening bleeding in a patient who could not receive 
protamine. The Heparin Removal Device is still await- 
ing Food and Drug Administration (FDA) approval for 
clinical evaluation. 
A 44-year-old woman with diabetes was admitted to 
The University of Texas Medical Branch Hospital be- 
cause of progressive angina pectoris with recent epi- 
sodes of angina at rest. She had diabetes ince the age 
of 18 years. Her insulin regimen included 50 units of 
NPH insulin and 5 units of regular insulin a day. She 
had end-stage renal disease and had been undergoing 
hemodialysis for the past 2 years. Other problems 
included severe peripheral vascular disease necessitat- 
ing amputation of the right forearm below the elbow 1 
year before admission after a failed polytetrafluoroeth- 
ylene graft for dialysis access. 
Attempts at stabilization of the angina pectoris with 
medical therapy were not successful and she underwent 
cardiac atheterization, which showed severe three-vessel 
coronary artery disease. On November 30, 1993, she 
underwent coronary artery bypass grafting to four distal 
vessels, which included a free left internal mammary 
artery grafl to the lefl anterior descending coronäry 
artery. At operation, the patient was found to have severe 
diffuse coronary artery disease with marked calcification 
of all of the coronary arteries including the areas of 
anastomosis on two of the vessels. After revascularization, 
she had good hemodynamics and was weaned from CPB 
with a cardiac index of 3.1 L/min per square meter and 
a blood pressure of 130/60 mm Hg. A test dose of 
protamine sulfate was administered into the left atrial 
line, after which she promptly had a severe reaction 
manifested by pulmonary vasospasm and systemic hy- 
potension. The pulmonary artery pressure increased to 
52 mm Hg systolic followed by acute right heart failure, 
a marked fall in the left atrial pressure to less than 5 
mm Hg, and a drop in systemic blood pressure to below 
40 mm Hg systolic. She required brief open cardiac 
massage and epinephrine administration before the 
hemodynamics were restored to a satisfactory state 
approximately 5 minutes later. Although the Heparin 
Removal Device was available, we realized it was not 
approved even as an investigational device, and we 
attempted conventional therapy. Additional protamine 
was withheld, hemostasis was obtained, and the chest 
was closed with what was believed to be minimal 
bleeding considering her fully anticoagulated state. The 
ACT was 459 seconds before she was transferred from 
the operating room. 
By the time she had arrived in the intensive care unit, 
brisk bleeding had begun, with chest tube drainage of 
2400 ml in the first hour after arrival. In addition to her 
heparinized state (ACT of 427 seconds), she also had a 
significant coagulopathy with evidence of fibrinolysis. 
The partial thromboplastin time was more than 150 
seconds, prothrombin time 48 seconds, fibrinogen level 
209 gin/dl, fibrin degradation products greater than 20 
Bg/ml, and platelet count 130,000/xl. She was returned 
to the operating room, the sternotomy was opened, and 
the mediastinum reexplored. No significant specific 
bleeding sites were found, but hemostäsis was still 
inadequate and bleeding continued. The combination 
of her heparinized state and severe coagulopathy, in the 
presence of end-stage renal failure, made it unlikely 
that the bleeding could be controlled without massive 
use of blood bank resources and placing her at great 
risk. We therefore decided to use the Heparin Removal 
Device. After obtaining verbal approval for compas- 
sionate one-time use of this FDA unapproved evice 
from the chairman of our institutional review board, we 
implemented the procedure. The dual-flow venovenous 
cannula was inserted through the atriotomy and was 
attached to a heparin-coated xtracorporeal circuit that 
removes blood from the inferior vena cava by a roller 
pump. That then propels the blood forward through the 
plasma separator and subsequently back to the other 
arm of the venovenous cannula. Within the curesis 
device, hollow fibers allow for plasmapheresis to occur. 
The heparinized and separated plasma comes into 
contact with the Heparin Removal Device sorbent 
material, which then absorbs the heparin and immobi- 
lizes it by means of a poly-L-lysine ligand. The plasma 
then spontaneously reenters the blood pathway as the 
blood circulates through the curesis device and returns 
to the right atrium through the proximal port of the 
double-lumen catheter. 
The Heparin Removal Device was used with a circula- 
tion rate of 500 tal/min for 25 minutes. Fig. 1 shows the 
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time course of the ACT over this period of heparin 
removal. The ACT after completion of this treatment was 
160 seconds, whereas the baseline ACT before CPB was 
192 seconds. Other coagulation studies, however, showed 
a persistent coagulopathy that was corrected over the hext 
4 hours with infusion of fresh frozen plasma and cryopre- 
cipitate. She was also treated with epsilon aminocaproic 
acid to correct abnormal fibrinolysis. The chest tube 
output was 300 to 400 ml/hr for the first 4 hours after 
heparin removal but diminished to an insignificant level, 
and she did well thereafter. 
No alternatives to protamine for heparin reversal are 
currently available. Although platelet factor 4 has been 
shown to be an effective neutralizer of heparin, 2 it is in the 
early stages of investigation and will likely not be available 
in the near future. The Heparin Removal Device uses a 
plasmapheresis f lter that is widely used clinically but has 
a resin added to the plasma compartment that binds and 
removes heparin. This approach to heparin removal has 
great potential merit as an alternative to protamine. It 
awaits a phase 1 clinical trial after FDA review and 
approval as an investigational device. 
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PRELIMINARY RESULTS OF DEFEROXAMINE AND L1 TREATMENT OF SPINAL 
CORD ISCHEMIA 
David G. Reuter, PhD, MD, Willis A. Tacker, Jr., MD, PhD, Charles F. Babbs, MD, PhD, 
Stephen F. Badylak, DVM, PhD, MD, William D. Voorhees III, PhD, and Peter E. Konrad, PhD, MD, 
West Lafayette, Ind. 
Vascular surgery necessitating aortic occlusion pro- 
duces spinal cord ischemia, which can subsequently ead 
to paraplegia. Previous studies suggest lipid-rich central 
nervous system tissue is sensitive to amplification of 
ischemic injury by free radical mechanisms that lead to 
lipid peroxidation. 1 Drugs that prevent free radical pro- 
duction and thus lipid peroxidation offer promise as a way 
to protect he spinal cord during periods of ischemia. 2 The 
agents deferoxamine and 1,2-dimethyl-3-hydroxypyrid-4- 
one (L1) are postulated to inhibit iron-catalyzed lipid 
peroxidation. Deferoxamine is a water-soluble iron chela- 
tor that has been shown to attenuate reperfusion i jury in 
isolated rat hearts. 3 L1 is a novel lipid-soluble iron 
chelator that has been shown to effectively chelate excess 
iron in a study of chronic transfusional iron overload (i.e., 
j3-thalassaemia). 40ur  goal was to use these two drugs to 
test the hypothesis that iron plays an important role in the 
pathophysiologic reactions leading to spinal cord damage 
attendant to ischemia nd reperfusion. 
Our preliminary study was performed in two stages. We 
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first developed a model of spinal cord ischemia that 
produced paraplegia in a majority of dogs. 5 The second 
phase of our study used the initial series of dogs as 
historical controls to determine if treatment with deferox- 
amine or L1 would significantly improve the neurologic 
outcome or histopathologic damage. 
In the second phase of our study, 13 mongrel dogs were 
sequentially divided into a deferoxamine-treated group 
(n = 5) and an L1 group (n = 8). The dogs were 
pretreated with atropine sulfate 0.4 mg/kg subcutaneously 
and acetylpromazine 0.22 mg/kg subcutaneously and were 
anesthetized with thiopental 9 to 13 mg/kg intravenously. 
After intubation, nitrous oxide was delivered by inhalation 
in a 1:2 ratio with oxygen, and anesthesia was maintained 
by repeated intravenous boluses of thiopental. A balloon 
catheter was inflated in the aorta just distal to the left 
subclavian artery to achieve spinal cord ischemia, and the 
duration of ischemia was determined by the amplitude 
reduction of the mean evoked potential signal, as it was in 
our initial study. The details of the evoked potential 
stimulaton, histopathologic s oring, regional blood flow 
studies, and neurologic assessment are identical to phase 
1 of the study, s In the first group of dogs, deferoxamine 25 
mg/kg was infused intravenously over a 20-minute period, 
starting 30 minutes before aortic occlusion. Another 25 
mg/kg dose of deferoxamine was administered over a 
20-minute period beginning 10 minutes before reperfu- 
sion. In the other group, L1 25 mg/kg was administered 
intravenously according to the same protocol. All animals 
received humane care in compliance with the "Principles 
